Zefiro founder criticizes board actions, meeting delay

Executive Summary

• Dr. Talal Debs, founder and former chairman of Zefiro Methane Corp., issued a critical update to shareholders alleging that current management is engaging in self-serving tactics to entrench themselves ahead of an upcoming proxy contest.
• Debs accuses the board of delaying the annual shareholder meeting from 2025 to March 4, 2026, denying shareholders their legal right to vote on the company's future.
• The release highlights specific grievances including excessive executive compensation with "golden parachutes," unnecessary share dilution through debt settlements, and suspicious insider trading patterns designed to manipulate stock prices and consolidate control.

Key Details

• Proxy Contest & Meeting Delay:
  • Shareholders (led by Dr. Debs and XMC) requisitioned a meeting by Dec. 31, 2025.
  • The company obtained an exemption and scheduled the Annual and Special Meeting for March 4, 2026.
  • Debs alleges this delay is a tactic to improve the board's chances in the upcoming vote.
• Executive Compensation & "Golden Parachutes":
  • Four senior executives (including Interim CEO Catherine Flax and Interim CFO Michael Downs) signed employment agreements on June 4, 2025.
  • Agreements include "single-trigger" change of control payments effective even if employment is not terminated (e.g., in a contested election).
  • Entitlements include a full year's salary and benefits.
  • Estimated total payout if triggered in Q1 2026: Up to $3 million (U.S.), representing ~20% of market cap.
  • Includes repayment of outstanding debt and interest owed predominantly to Ms. Flax.
  • No such provisions existed during Debs' tenure.
• Insider Trading & Stock Manipulation Allegations:
  • On Dec. 1, 2025, the company announced four board members purchased 723,000 shares.
  • Debs claims these purchases distorted the share price, which rose 8% on Nov. 17 and 19% between Nov. 18-25.
  • Insiders accounted for ~42% of combined US/CA trading volume during that period.
  • Director Daryl Heald purchased 147,500 shares on Nov. 25 alone (89% of Canadian volume that day).
  • Director Jonson Sun purchased 291,500 shares between Sept. 30 and Nov. 4, 2025.
  • Debs alleges insiders stopped purchasing once they issued celebratory news releases to avoid further SEDI disclosure requirements.
• Debt Settlements & Dilution:
  • On Nov. 28, 2025, the company issued 1,127,273 common shares and 400,000 stock options to related parties to settle $407,855.97 of debt.
  • Deemed price: 27.5 cents/share (vs. market close of 31 cents).
  • Debs argues this unnecessarily diluted shareholders and placed shares into "friendly hands" (including a company partly owned by Director Jonson Sun).
  • Debs questions why lower-cost debt was retired via equity while more expensive debt (including $1.8M USD held by CEO Flax) remains.
  • Debs asserts failure to offer pro-rata maintenance of interest is a breach of the XMC Group's investor rights agreement.
• Operational & Strategic Criticisms:
  • Debs claims current management is "resting on the laurels" of the previous team.
  • Alleged cuts to long-term growth prospects include:
    • Decommissioning of Zefiro Lifecycle Solution (ZLS).
    • Discontinuation of proprietary AI-driven mapping tool for leaking oil/gas wells.
    • Termination of the team leader for Zefiro's only successful carbon credit batch.
• Shareholder Position:
  • Dr. Debs and XMC beneficially own 20,914,750 shares (27.488% of issued/outstanding).
  • Debs does not intend to vote 500,000 personal shares.
  • A website (www.zefirotruth.com) has been established to detail nominees for the upcoming proxy contest.

Notable Quotes

• "The board of directors at Zefiro has made much of recent positive news... recent filings detail actions that appear to be an attempt at 'entrenching' current management at the expense of Zefiro shareholders."
• "Meanwhile, the board has been denying shareholders the opportunity to vote on the future of their own company by failing to hold an annual meeting in 2025 as required by law and delaying the meeting until March 4, 2026."
• "Absent these additional details, investors may have assumed the company's share price appreciation was driven primarily by the market's response to its Q1 2026 results, rather than by insider purchases."
• "Dr. Debs is of the view that the current management team is 'resting on the laurels' of its predecessors while at the same time diminishing the company's future prospects."